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Spinal muscular atrophy (SMA) is a neurodegenerative disease that causes
progressive muscle weakness, which primarily targets proximal muscles.
About 95% of SMA cases are caused by the loss of both copies of the SMN1
gene. SMN2 is a nearly identical copy of SMN1, which expresses much less
functional SMN protein. SMN2 is unable to fully compensate for the loss of
SMN1 in motor neurons but does provide an excellent target for therapeutic
intervention. Increased expression of functional full-length SMN protein from
the endogenous SMN2 gene should lessen disease severity. We have developed
and implemented a new high-throughput screening assay to identify small
molecules that increase the expression of full-length SMN from a SMN2
reporter gene. Here, we characterize two novel compounds that increased
SMN protein levels in both reporter cells and SMA fibroblasts and show that
one increases lifespan, motor function, and SMN protein levels in a severe
mouse model of SMA.
INTRODUCTION
Spinal muscular atrophy (SMA) is a neurodegenerative disorder
that presents as progressive muscle wasting and loss of motor
function. It is caused by the degeneration of motor neurons,
speciﬁcally the anterior horn cells of the spinal cord and is one of
the leading heritable causes of infant mortality worldwide
(Crawford & Pardo, 1996; McAndrew et al, 1997; Pearn, 1978).
SMA is caused by a deﬁciency of the SMN protein. There are
two nearly identical SMN genes, the telomeric SMN1 and the
centromeric SMN2 (Boda et al, 2004; Echaniz‐Laguna et al, 1999;
Monani et al, 1999). While the protein coding capacity of SMN2
is identical to that of SMN1 (Jablonka et al, 2000a), there is a
translationally silent nucleotide variation in exon 7 of SMN2
(Lorson et al, 1999; Monani et al, 1999). This C to T transition
results in alternative splicing of SMN2 and exclusion of exon 7.
From SMN1, >95% of the transcripts include exon 7 and
express the full‐length SMN protein. From the SMN2 mRNA,
85% of the messages lack exon 7 (Gavrilov et al, 1998;
Gennarelli et al, 1995; Lorson et al, 1999; Monani et al, 1999) and
express a truncated form of the protein (SMND7). The SMND7
protein is inactive and cannot fully compensate for the loss of
SMN1 (Burnett et al, 2009; Lorson & Androphy, 2000; Lorson
et al, 1998).
SMN2 is a potent disease modiﬁer for SMA, and there is
an inverse relationship between the number of copies of SMN2
and clinical severity. Most cases of SMA harbour homozygous
deletions of the SMN1 gene but retain at least one copy of SMN2
(Brahe et al, 1996; Campbell et al, 1997; Hahnen et al, 1995,
1996, 1997; Jablonka & Sendtner, 2003; Melki, 1997; Talbot
et al, 1997; van der Steege et al, 1996; Velasco et al, 1996). The
relationship between SMN2 copy number and disease severity
has been conﬁrmed in SMA mouse models (Hsieh‐Li et al, 2000;
Michaud et al, 2010; Monani et al, 2000). Homozygous deletion
of the single copy of the mouse Smn gene is embryonic lethal
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(Schrank et al, 1997). Introduction of two copies of the
human SMN2 transgene supports viability but these animals
have motor function defects and an average life span of 4–
6 days. Increasing the number of SMN2 copies decreases
disease severity and increases life span. High copy number
SMN2 transgenic mice were phenotypically ‘normal’ (Monani
et al, 2000).
Because SMA carriers with only one copy of SMN1 are
clinically asymptomatic, 50% of normal SMN levels should
protect from disease. If SMN2 can be stimulated to express
more full length SMN mRNAs, synthesis would be directed
towards increased amounts of the active SMN protein (Cherry
& Androphy, 2012). Although the threshold level of SMN
necessary to maintain motor neurons is not known, only 10–
15% of SMN2 transcripts contain exon 7 and express functional
SMN, so doubling or tripling the amount of full length SMN2
mRNA should be clinically signiﬁcant (Meyer et al, 2009).
There is no treatment for SMA. Therapeutic modalities for
treatment of SMA that are being actively pursued include
oligonucleotides to restore SMN2 exon 7 inclusion, gene transfer
using viral vectors, and cell replacement with motor neuron
differentiated stem cells (Corti et al, 2008, 2010; DiDonato
et al, 2003; Dominguez et al, 2011; Foust et al, 2010; Hua
et al, 2010, 2011; Passini et al, 2010, 2011; Porensky et al, 2012;
Valori et al, 2010;Williams et al, 2009). Several laboratories have
undertaken screens for drug‐like compounds that increase
cellular levels of the SMN protein from the SMN2 gene.
Compounds that have been shown to increase SMN2 expression
include various histone deacetylase (HDAC) inhibitors, aclar-
ubicin, indoprofen, splicing modiﬁers, a DcpS inhibitor, anti‐
terminators, proteasome inhibitors and inhibitors of multiple
signalling pathways (Andreassi et al, 2001; Avila et al, 2007;
Bowerman et al, 2010, 2012; Burnett et al, 2009; Chen
et al, 2012; Farooq et al, 2009; Garbes et al, 2009; Hahnen
et al, 2006; Hastings et al, 2009; Heier & DiDonato, 2009;
Jarecki et al, 2005; Kernochan et al, 2005; Kwon et al, 2011; Lunn
et al, 2004; Makhortova et al, 2011; Narver et al, 2008; Singh
et al, 2008; Wolstencroft et al, 2005; Zhang et al, 2001, 2011).
Because many of these activators are non‐speciﬁc and can
have off‐target effects, their long‐term safety remains to be
determined. Compounds that have advanced into clinical trials
have demonstrated mixed results. There is clearly need for
additional drug candidates (Darras & Kang, 2007; Sproule &
Kaufmann, 2010; Sumner, 2006).
We previously reported the development of an SMN2‐
luciferase reporter assay to identify compounds that increase
SMN expression from the SMN2 gene (Cherry et al, 2012).
This assay has been used at two screening centres to screen
over 300,000 compounds (Cherry et al, 2012; Xiao et al, 2011).
From a screen of 115,000 compounds at the Laboratory for
Drug Discovery in Neurodegeneration (LDDN), 462 hits were
identiﬁed and 19 ‘high’ priority compounds were selected on
the basis of their activity, potency, speciﬁcity, lack of overtly
toxic functional groups, and potential tractability for chemical
modiﬁcation. Here we report the selection and further
characterization of two compounds as potential leads for new
SMA therapies.
RESULTS
Hit conﬁrmation
As described previously (Cherry et al, 2012), 492 hits were
identiﬁed from a library of 115,000 compounds. The activity
of these compounds was conﬁrmed in the SMN2‐luciferase cell
line and counter‐screened with a control cell line expressing
luciferase from the minimal SV‐40 promoter (SV40min‐
luciferase). Two‐hundred and ninety four compounds repro-
duced >60% increase in luciferase activity and of these 18 were
selected on the basis of potency, strength of activation, dose
dependency, speciﬁcity against luciferase control, and favour-
able chemical properties. Each of these compounds showed
greater than 100% increase in luciferase activity in the SMN2‐
luciferase cell lines and stimulated the control reporter cell lines
by less than 40%. All lacked overtly toxic functional groups
and had chemical scaffolds that were tractable to chemical
modiﬁcation.
These compounds were re‐screened using the SMN1‐
luciferase, SMN2‐luciferase cell lines and the SV40min‐luciferase
control cell lines (Supporting Information Fig S1). This panel
of reporters allows for the discrimination between compounds
that target general SMN transcription and protein expression
and turnover and SMN2 speciﬁc splicing or other SMN2
speciﬁc mechanism, while also allowing for the detection of
non‐speciﬁc inhibitors. Of the 18 compounds re‐tested in dose
response experiments, all increased luciferase expression by
>60% (data not shown). We previously reported preliminary
data for 3 of the 18 primary hits from this screen; LDN‐72939,
LDN‐79199 and LDN‐109657 (Cherry et al, 2012). Here we
further characterize LDN‐109657 and two new structural classes
(Fig 1A).
The related analogs, LDN‐75654, LDN‐75676 and LDN‐75847
represent a new class of SMN2 inducing compounds. Each
contains an oxazole carboxamide backbone. Of these three
compounds, LDN‐75654 was more potent and had greater
activity, with a >240% (3.4‐fold increase) in luciferase activity
and an average EC50 of 2 mM (Fig 1B). LDN‐75654 was chosen
for further characterization as the preferred lead from this series.
LDN‐76070 was identiﬁed as a singleton in our initial screen. It
elicited >180% or 2.8‐fold increase in luciferase activity with an
average EC50 of 8.3 mM (Fig 1B). The dose response curve from
LDN‐109657 is presented to illustrate the activity and speciﬁcity
proﬁle, which is similar to that of LDN‐76070, but is more potent
and promotes higher levels of activation (Fig 1B). The relative
activity and potency for these compounds is summarized in
Fig 1C.
To conﬁrm that the increased luciferase activity corresponded
to an increase in the amount of SMN‐luciferase fusion protein,
Western blots on lysates from compound treated SMN2‐
luciferase reporter cells were performed with an antibody to
luciferase. The level of SMN‐luciferase protein increased
following incubation of SMN2‐luciferase reporter cells for
24 h with compounds LDN‐75654, LDN‐76070 and LDN‐
109657 (Fig 1D). These increases in protein level were
comparable to the increases observed for luciferase activity in
the dose response curves (Fig 1B).
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Analysis of mRNA in SMN2-luciferase reporter by qRT‐PCR
Based on the SMN2 reporter design, we predict that the
compounds identiﬁed through this screen could increase SMN
protein levels by stimulation of SMN transcription, exon 7
inclusion in the SMN2 pre‐mRNA, or inhibition of SMN protein
turnover (Supporting Information Fig S1; Cherry et al, 2012).
Comparison of the activity of these compounds in the reporter
cell lines can provide insight into the mechanisms of action for
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Figure 1. Hit conﬁrmation in the reporter cells.
A. Structures of the hits LDN-75654, LDN-75676, LDN-75847, LDN-76070 and LDN-109657.
B. Dose response experiments. Each compound was tested with the reporter cell lines at the concentrations; 0.04, 0.12, 0.37, 1.11, 3.33, 10, 30 mM. Black—
SMN2-luciferase cells; blue—SMN1-luciferase cells; red—SV40min-luciferase control cells. Y-axis represents % activation over DMSO control. All points were
tested in quadruplicate and plotted as mean  SEM. Curves were created by linear regression using Prism4 (GraphPad Software Inc.).
C. Summary of dose response experiments denoting average potency as EC50 (concentration required to achieve 50% of themaximal drug response) and average
Emax (maximal % increase in luciferase activity observed with treatment). For each calculation, n  4 and data are presented as mean  SEM.
D. Increase in SMN-luciferase fusion protein with hits. SMN2-luciferase reporter cells were incubated in presence of increasing amounts of compound for 24 h.
Lysates were blotted with antibodies to luciferase and b-actin. Experiments were performed three times. Blots shown are representative.
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these compounds. The SMN1‐luciferase and SMN2‐luciferase
reporters allow expression of an SMN‐luciferase fusion protein
from either the SMN1 or SMN2 3.4 kB promoter in the context of
their respective cDNA and the genomic exon 6–8 splicing
cassette. Activation of the SMN1‐luciferase reporter would
suggest generalized increase in SMN expression or protein
levels. Activation of the SV40min‐luciferase reporter, which
drives luciferase expression from the SV40 promoter, would
suggest non‐speciﬁc activity. All compounds presented in Fig 1
displayed some low level of non‐speciﬁc activation of the
SV40min‐luciferase reporter; none activated SV40min‐luciferase
to the same extent as the activation observed in the SMN2‐
luciferase reporter cell line. For example LDN‐76070 and
LDN‐109657 caused an increase in SMN2‐luciferase levels, but
also increased luciferase expression in the SMN1‐luciferase and
SV40min‐luciferase reporters to a much lesser degree (Fig 1B).
These results suggest that these compounds act through a
general mechanism that target both SMN1 and SMN2. LDN‐
75654 and its analogs, LDN‐75676 and LDN‐75847, increased
SMN2‐luciferase expression but appeared to inhibit luciferase
expression from the SMN1‐luciferase reporter, suggesting that
these compounds have target speciﬁcity for SMN2 (Fig 1B).
Quantitative reverse transcriptase PCR (qRT‐PCR) was used
to analyse SMN‐luciferase mRNA from control and compound‐
treated SMN2‐luciferase cells. The upstream primer for each
pair overlaps a unique restriction site present only in the
reporter and will amplify only the transcripts derived from
SMN‐luciferase reporter (Fig 2A). To measure changes in the
level of total SMN‐luciferase mRNA, primers that amplify
both the full‐length (exon 7 included) and D7 (exon 7 excluded)
SMN‐luciferase transcripts were used (Fig 2A; primers 1 and 3).
To speciﬁcally measure the amount of full‐length exon 7
included SMN‐luciferase transcripts, a primer in exon 7 was
paired with the upstream primer (Fig 2A; primers 1 and 2).
For each sample the percent change in the amount of total
SMN‐luciferase transcripts (white bar), full‐length exon 7
included SMN‐luciferase transcripts (grey bar), and SMN2‐
luciferase activity (black bar) was plotted (Fig 2B). Compounds
that solely stimulate transcription should predominantly
increase the amount of total SMN‐luciferase transcripts with a
proportional increase of exon 7 included transcripts. Com-
pounds that stimulate exon 7 inclusion should increase
the amount of full‐length exon 7 included transcripts with
little to no change in the expression of total SMN‐luciferase
transcripts.
LDN‐76070 treatment resulted in an increase in total
transcript, with a concurrent increase in exon 7 included
mRNA. As would be expected, the increase in SMN‐luciferase
activity closely mirrored the increase in the exon 7 included
transcripts (Fig 2B; grey and black bars). A similar pattern of
mRNA expression was observed with LDN‐109657. It can be
inferred that these compounds increase SMN transcription.
LDN‐75654 had a different qRT‐PCR proﬁle (Fig 2B). Little to
no change in mRNA levels was observed except at its highest
concentration. However, the luciferase activity showed a
concentration dependent increase, suggesting that LDN‐75654
exerts its effect through a post‐transcriptional mode‐of‐action.
Increases in total SMN protein levels and SMN gems in SMA
derived ﬁbroblasts
To conﬁrm the ability of the compounds to increase SMN
expression from the SMN2 gene, their effects on endogenous
SMN protein levels were examined. It is common practice to use
SMA derived primary ﬁbroblasts to assess SMN protein levels
in response to SMN2 inducing compounds. We use the 3813
(SMN1/; SMN2þ/þ) and 3814 (SMN1þ/; SMN2þ/þ) cells.
3813 cells express low levels of endogenous SMN protein, while
3814 cells, which carry a single copy of SMN1, express 3–5 times
more full‐length SMN protein (Coovert et al, 1997) (Fig 3A).
The activity of LDN‐109657 increases SMN protein levels in
3813 ﬁbroblasts by twofold at a concentration of 370 nM (Cherry
et al, 2012). LDN‐75654 and LDN‐76070 were tested for their
effect on total endogenous SMN protein levels. 3813 ﬁbroblasts
were treated with varying concentrations of each compound for
72 h and protein was quantiﬁed by immunoblot. We observed
that these primary ﬁbroblasts were sensitive to lower concen-
trations of compound than those used in the immortalized
HEK293 reporter cell lines. The average increase for each of
these compounds was determined from multiple experiments.
LDN‐75654 treatment resulted in dose dependent increases in
SMN levels with a maximum average increase of 1.9  0.5‐fold
at a dose of 1.1 mM. LDN‐76070 was most active at a dose of
370 nM with a maximal increase in SMN protein level of
1.8  0.3‐fold averaged over three experiments. The immuno-
blots presented in Fig 3A are from a single experiment and
are representative of the overall pattern of SMN expression
observed in multiple experiments.
Another useful characteristic of the SMN protein is its
localization to large nuclear bodies called ‘gems’ (Lefebvre
et al, 1997; Liu & Dreyfuss, 1996). The relative number of gems
per nucleus correlates positively with total SMN protein level
and inversely with disease severity in a wide array of patient
ﬁbroblasts (Coovert et al, 1997; Patrizi et al, 1999). Unlike the
Western blot for total SMN protein, the gem assay scores SMN
levels on a cell‐by‐cell basis and focuses on the more stable gem
associated pools of SMN protein. This approach is not impacted
by the effects these compounds may have on cell proliferation.
This assay allows for shorter treatment times and the use of
higher compound concentration as is seen in the gem count
experiments in Fig 3B and C.
Fibroblasts (3813) were treated as described above for the
quantitative immunoblot assay and assayed for SMN immuno-
ﬂuorescent staining in the nucleus. The 3813 cells had an
average of 14  4.7 gems per 100 nuclei and the 3814 cells had
an average of 84  4.8 per 100 nuclei. The immunoﬂuorescent
images in Fig 3B illustrate the increase in the number of gems
observed with the addition of 3.3 mM compound for 48 h.
Treatment with either compound increased the number of
gems in 3813 ﬁbroblasts by nearly twofold at concentrations
between 370 nM and 3.3 mM. (Fig 3C).
Additive effects of compounds used in combination
Based on the qRT‐PCR data, we hypothesized that LDN‐76070
affects transcription, while LDN‐75654 functions at the post‐
transcriptional level either by stimulating translation or
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stabilizing SMN protein. To further explore their activities,
the compounds were tested together in pairs and individually
with the pan HDAC inhibitor suberoylanilide hydroxamic acid
(SAHA) in the SMN2‐luciferase reporter assay. SAHA has been
shown to increase SMN protein expression by increasing
transcription of the SMN gene and by increasing exon 7
inclusion in SMN2 transcripts (Hahnen et al, 2006). In this assay,
the SMN2‐luciferase reporter cells were treated at six doses
increasing from 124 nM to 30 mM of one compound and
combined with either DMSO or a second compound at
concentrations of 1.1, 3.3, or 10 mM. All data points were
collected in triplicate and six‐point dose response curves were
generated for each pair.
When a ﬁxed dose of LDN‐76070 was mixed with LDN‐75654
in a dose response experiment, the amplitude of SMN2‐
luciferase activation was enhanced in comparison to LDN‐
Figure 2. Analysis of SMN‐luciferase fusion transcripts by qRT‐PCR.
A. A schematic of the primer design for qRT-PCR. Primer pairs were chosen to amplify only the SMN-luciferase fusion transcripts but not endogenous SMN. Primer
1 overlaps a unique Xho I site. Primers 1 and 2 can only amplify full-length SMN-luc transcripts that contain exon 7. Primers 1 and 3 amplify SMN-luc reporter
transcripts (both exon 7 included and excluded).
B. Graph of qRT-PCR results. Quantitation of luciferase activity (black bars), total reporter transcripts (white bars), and exon 7 included reporter transcripts
(grey bars). Transcripts were quantitated by qRT-PCR. Cells were treated at three increasing concentrations for 24 h. Percent increase was calculated in
relation to treatment with DMSO and normalized to GAPDH. For each data point, n  3 and data are presented as mean  SEM.
Research Articlewww.embomolmed.org
Jonathan J. Cherry et al.
EMBO Mol Med (2013) 5, 1103–1118  2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1107
75654 alone (DMSO‐black line, Fig 4A). This augmentation was
observed as the concentration of LDN‐76070 increased from
1.1 mM (red), 3.3 mM (purple), and 10 mM (blue). In the
reciprocal experiment, a dose response of LDN‐76070 in
combination with a ﬁxed dose of LDN‐75654 revealed similar
additive effect (Fig 4B). qRT‐PCR analysis demonstrated that
LDN‐109657 increased the amount total SMN2‐luciferase tran-
scripts, suggesting that it also acts at the transcriptional level
(Fig 2B). As expected, when LDN‐109657 was paired with LDN‐
75654, an additive increase in activity was observed (Fig 4C).
However when LDN‐76070 was combined with LDN‐109657,
there was no increase in activity (Fig 4D). Instead, at higher
doses, LDN‐109657 masked the dose response curve of LDN‐
76070 eliciting the maximal luciferase irrespective of LDN‐
76070 concentration. We propose that the increase in response
amplitude results from a combination of compounds that
cooperate through separate mechanisms or pathways, while an
apparent increase in potency with no response in amplitude is
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A Figure 3. Activity of primary hits in primary
human ﬁbroblasts.
A. Total endogenous SMN protein in 3813 fibro-
blasts. Primary human fibroblast lysates from
carrier (3814; SMN1þ/; SMN2þ/þ) and SMA
(3813; SMN1/; SMN2þ/þ) derived cells were
blotted with antibodies to SMN and a-tubulin.
Cells were treated for 48 h with increasing
concentrations of compound. Experiments were
performed three times.
B. Representative pairs of images of SMN gems in
3813 or 3814 SMA fibroblasts. 3813 primary
fibroblast were treated with DMSO, 3.3 mM LDN-
76070, or 3.3 mM LDN-75654 for 48 h. (SMN-
green and DAPI-blue) The scale bar is 10 mM.
C. Quantification of gem data. Increases in gem
numbers were quantified by incubating cells for
48 h in increasing amounts of compound, fixed,
and imaged as above. Graphs plot the number of
gems per 100 nuclei where 3813 cells are
designated by green bars and 3814 by blue bars.
Data are presented as mean  SEM for three
experiments and was analysed using Prism4
(GraphPad Software Inc.). Each data point was
compared to DMSO control using unpaired t-test
with p-values shown. p < 0.05; p < 0.01;
p < 0.001.
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the result of additive effects of two compounds with similar
modes of action. Pairing SAHA with LDN‐75654 produced a
dramatic effect, resulting in a >threefold additive increase in
activity at all concentrations (Fig 4E). Pairing SAHA with the
putative transcriptional activator LDN‐76070 resulted in only a
slight additional increase in activation at the highest concen-
trations of SAHA (Fig 4F).
To further characterize the relationship between the two
scaffolds, we examined them in combination using a constant
ratio design (Chou, 2006). In this experiment, each compound is
tested alone or in combination with a second compound. In each
case, the compounds are paired in a constant ratio that is
centered on their EC50. For these experiments, the effective EC50
value for both LDN‐75654 and LDN‐76070 was 6.25 mM while
the EC50 for SAHA was 1.25 mM. The constant ratio between
LDN‐75654 and LDN‐76070 was 1:1 and the constant ratio
between these compounds and SAHA was 5:1. The activity of
each compound individually (red and blue) at each data point
can be added to the activity of its partner for that same data point
and a plot for the theoretical additive curve is used as a threshold
for additivity (Fig 4G–I; green line). If the experimental curve
(purple) for the compounds in combination matches this
curve, the effect of these compounds in combination is additive.
If the experimental curve is above the theoretical additive curve,
the activities of these compounds are more than additive and
may be acting synergistically. If the compounds fall below the
theoretical curve, they may be acting through a similar or related
mechanism and thus diminishing the activity of each compound
individually. It is also possible that such compounds are acting in
opposition to one another and the interaction could be
considered antagonistic. While the single dose curves showed
increased amplitude with combinations of LND‐76070 with
75654 (Fig 4A and B) and SAHA with LDN‐75654 (Fig 4E), the
constant ratio design suggests that the relationships between
these compounds are synergistic (Fig 4G and H). In this set of
experiments, the combination of LDN‐76070 with SAHA also
resulted in luciferase activity that was greater than additive (Fig
4I). However, the additive effects were less than those observed
in the pairing of LND‐76070 with 75654 and SAHA with LDN‐
75654 (Fig 4G and H).
Efﬁcacy in SMND7 SMA mice
LDN‐75654 and LDN‐76070 were examined for aqueous
solubility, mouse liver microsome stability, and HDAC inhibitor
activity. Due to its limited solubility and poor chemical
tractability, LDN‐109657 was excluded from further analysis.
These data are summarized in Table 1. LDN‐75654 was soluble
at a maximum concentration of 10 mg/ml in PBS (pH 7.0) and
had a relatively short half‐life in mouse live microsomes. LDN‐
76070 appeared to be more stable and had a 40 min half‐life in
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Figure 4. Dose response proﬁles for compounds in combination.
A–F. Compounds were assayed in a dose response alone or in the presence of 3 fixed concentrations of a second compound (A) LDN-75654 versus LDN-76070,
(B) LDN-76070 versus LDN-75654, (C) LDN-75654 versus LDN-109657, (D) LDN-76070 versus LDN-109657, (E) SAHA versus LDN-75654, (F) SAHA versus
LDN-76070.
G–I. For constant ratios combinations, compounds were tested alone or in combination. The combined compounds were tested at concentrations that varied at a
constant ratio for all data points. The ratio is based on the difference in EC50 values for each compound separately. The blue and red lines illustrate the curves
for each compound independently. The green line represents the theoretical additive threshold for the compounds combined. The purple line represents the
experimental data for the compounds in combination. (G) LDN-75654 versus LDN-76070, (H) SAHA versus LDN-75654, (I) SAHA versus LDN-76070. Graphs
plot the increase in luciferase activity in relation to DMSO treated control. Y-axis represents % activation over DMSO. All points were tested in triplicate and
plotted as mean  SEM. Curves were created by linear regression using Prism4 (GraphPad Software Inc.).
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themouse liver microsomes, however, its maximum solubility in
PBS was <10 mg/ml.
To evaluate these compounds in animals, pilot experiments
were initiated using SMND7 (Smn/, SMN2þ/þ, SMND7þ/þ)
(Le et al, 2005). The compounds were administered either by
intraperitoneal (i.p.) or intracerebroventricular (i.c.v.) injection
into the SMA mice as previously described (Baughan et al, 2006;
Coady et al, 2008). Animals were treated for 3 days, starting on
postnatal day 1 (PND). On PND3, mice were sacriﬁced and
tissues were harvested.
Animals treated with 5 mg/kg LDN‐76070 showed increased
SMN protein in spinal cord and brain (Fig 5A). Treatment with
20 mg/kg LDN‐76070 caused a lesser increase in SMN protein in
both the spinal cord and brain while promoting a slight increase
in SMN levels in the liver. Treatment with LDN‐75654 had no
effect on SMN protein levels in either the muscle or liver. In the
brain and spinal cord, LDN‐75654 induced a slight increase in
SMN protein (Fig 5A). However, this increase was inconsistent
and varied among the small number of treated animals. A
second, appropriately powered study was set up to conﬁrm
these data. Due to the weak and inconsistent responses observed
with LDN‐75654 in the pilot experiments, LDN‐76070 was
chosen as the primary lead for in vivo validation in the SMA
mouse model. We chose to conﬁrm in vivo efﬁcacy using a dose
of 20 mg/kg to achieve higher in vivo concentrations following
i.p. administration.
LDN‐76070 was administered to SMND7 mice once daily by i.
p. starting on PND 2. Tissues were harvested from three treated
animals on PND 7 and compared to tissues from asymptomatic
heterozygous littermates, untreated, and DMSO (vehicle) treated
animals. Brain, spinal cord and muscle were assayed for total
SMN protein with the house keeping gene IP90 (calnexin) as a
loading control (Fig 5C). The mean increase of SMN protein
levels in the spinal cord of LDN‐76070 mice was over sixfold
greater than untreated or DMSO treated animals. This was close
to 90% of the protein detected in the heterozygous littermates
(Fig 5B). SMN protein levels also increased in brain by over
threefold, which corresponded to >30% of SMN detected in the
brains of heterozygous animals. There was no increase in
the amount of SMN protein in the muscle with LDN‐76070
treatment.
To assess the impact of LDN‐76070 on survival, daily
treatment of SMND7 animals with 20 mg/kg was continued
as long as feasible. The lifespan of treated animals was compared
to that of untreated and DMSO treated animals. We observed a
decrease in life span with DMSO treatment. The median survival
of untreated animals was 11.5 days, while DMSO treated animals
had a median survival of 6 days. Treatment with LDN‐76070
increased median survival to 17 days. This corresponded to a
180% (2.8‐fold) increase in lifespan over DMSO control animals
and 48% (1.4‐fold) over untreated animals (Fig 6A). In both
comparisons, the increase in lifespan was statistically signiﬁcant
with, p ¼ 0.00028 and p ¼ 0.00055, respectively.
Another metric to gauge the potential efﬁcacy of new therapies
in the SMND7 mice is weight gain from birth to peak. This
measurement is different than total weight as it incorporates the
variability in birth weight for this very severe model. Typically
mice range in birth weight from 1.2 to 1.9 g. The average birth
weight for the SMND7 mice was 1.42  0.2 g. In the survival
experiments, DMSO and untreated animals reached an average
peak weight of 2.93  1.5 and 3.33  1.1 g, respectively.
The weights of the animals were recorded each day and the
average weight gain from birth to peak for all animals in each
tested group was calculated (Supporting Information Fig S2).
LDN‐76070 treated mice produced a 250% gain in peak weight,
while weight increases in the DMSO treated and untreated
animals were less than 150% (Fig 6B). The average number of
days required to reach peak weight varied from 6.5 in DMSO, to
9.1 in untreated, and to 10.4 days in LDN‐76070 treated animals.
We also calculated the daily average weights for each of the
surviving animals, including the sicker, smaller animals that
died prematurely (on or before day 6). Since the median survival
of the DMSO treated animals was 6 days, the apparent increase
in their average weight on days 7 through 10 was the result of the
limited number of animals remaining; each of these had slightly
higher weights (Fig 6C and Supporting Information Fig S2).
However, the animals treated with LDN‐76070 still reached a
higher average peak weight of 5.05  0.9 g and had substan-
tially longer life span compared to either of the control groups
(Fig 6C and Supporting Information Fig S2).
The ‘time to right’ (TTR) test is a measure of gross motor
function (Butchbach et al, 2007b). All DMSO treated and four of
ten untreated SMA pups failed this test, the remaining animals
displayed an intermittent ability to right themselves. Further-
more, none of the control animals showed the ability to right
after PND 10 (DMSO group) and PND11 (Untreated group). SMA
pups treatedwith LDN‐76070 displayed a dramatic improvement
in the ability to turn over. Twelve of nineteen LDN‐76070 treated
animals displayed improved motor function over the course of
multiple days. This was most dramatic at PND 14 and 15 when
the average righting time for the surviving population was under
20 s. A few treated pups were able to turn over in as few as 5 s
andmaintained at this level of grossmotor function up to PND 16
(Fig 6D). Collectively, the data show statistically signiﬁcant
extension of life and motor capabilities with LDN‐76070
treatment in comparison to DMSO and untreated animals.
Table 1. Preliminary lead characterization
LDN‐75654 LDN‐76070
242.4  35 185.7  48 Activity luc reporter (% activation)
2.0 mM  0.9 8.3 mM  4.5 Potency luc reporter (EC50)
15 min 40 min Stability in mouse liver microsomes
10 mg/ml <10 mg/ml Solubility assay (mg/ml in PBS)
– – HDAC inhibitor activity
n.d. þþþþ (n ¼ 16) Ability to right in D7 micea
no increase >3-fold Protein increase in D7 miceb
n.d. 10 days Increase in median survival in D7 micec
n.d., not determined; a, ability to right is determined in time to right assay; b,
protein increase is determined in spinal cord and brain in relation to DMSO
treated SMA D7 littermates; c, median survival for DMSO treated SMA pups
was 6 days.
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DISCUSSION
SMA is primarily caused by the loss or mutation of both copies of
the SMN1 gene. The SMN gene is required for viability (Schrank
et al, 1997) and the copy number of SMN2 inversely correlates to
disease severity (Feldkotter et al, 2002; Harada et al, 2002; Monani
et al, 2000; Wirth et al, 1999). The potential to express functional
full‐length SMN protein and the presence of at least one copy in
nearly all SMA patients makes SMN2 an attractive therapeutic
target for the treatment for SMA. Although the threshold level of
SMN protein necessary to maintain motor neurons has not been
adequately determined, it is reasonable to predict that doubling or
tripling the amount of full length SMN protein should be sufﬁcient
to prevent or diminish clinical progression. Motor neurons appear
intact at birth in SMA murine models, so there appears to be a
temporal window for restoration of SMN and survival of motor
neurons (McGovern et al, 2008). Consistent with this, an inducible
mousemodel of SMA demonstrated that whole‐body restoration of
SMN decreases disease severity even if induction occurs after the
onset of symptoms (Lutz et al, 2011).
As a potent disease modiﬁer for SMA, SMN2 has become
a high priority target for SMA therapeutics. Many of the
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Figure 5. Increase in total SMN protein in SMND7
mice.
A. Pilot experiments in SMND7 mouse model.
Animals were treated daily for 3 days starting at
PND1 with compounds at various concentrations.
Tissues were harvested from two sets of animals,
brain and spinal cord from animals that received
compound by i.c.v. and muscle and liver from
animals that were injected by i.p. SMN protein
measured by semi-quantitative immunoblot and
normalized to actin. Increases in protein are
presented as fold increase when compared to
DMO treated SMA neonates.
B. Quantification of SMN protein levels in LDN-
76070 treated SMND7 animals. Starting on PND2,
Animals were injected daily with 20 mg/kg of
compounds by i.p. On PND7, animals were
sacrificed and tissues from brain, spinal cord, and
muscle were harvested. SMN protein measured by
semi-quantitative immunoblot and normalized to
the IP90 (calnexin) as a loading control. For each
data point, n ¼ 2 and data are presented as
mean  SEM. Increases in protein are presented
as fold increase when compared to DMO treated
SMA neonates.
C. Representative immunoblots of total SMN protein
expression in the brain, spinal cord, and muscle of
untreated, DMSO treated, or LDN-76070 treated
SMND7 animals. The images are from the same
blot with the same exposure.
Research Articlewww.embomolmed.org
Jonathan J. Cherry et al.
EMBO Mol Med (2013) 5, 1103–1118  2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1111
Figure 6. Activity of LDN‐76070 in SMND7 mice. Animals were injected with 20 mg/kg of each compound LDN-76070 (green; n ¼ 19) and compared to
untreated (red; n ¼ 10) or DMSO treated animals (black; n ¼ 10) Compound was administered i.p. once daily starting on post natal day 2 (PND).
A. Kaplan–Meier curve illustrates a significant increase in lifespan with compounds (Log-rank (Mantel–Cox) test; p ¼ 0.00028 in comparison to DMSO and
p ¼ 0.00055 in comparison to untreated animals).
B. Average percent weight gained from peak to birth. LDN-76070 treated animals (green) show a significant increase in percent weight gained from birth to peak
in comparison to DMSO (black) and untreated animals (red)(p ¼ 0.00005 and 0.00002, respectively; unpaired t-test).
C. The average weight for surviving members of each cohort is plotted daily. Data are presented as mean  SEM.
D. Treated animals (green) displayed an increase in the ability to tight themselves when compared to untreated (red) or DMSO treated animals (black).
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compounds in development are either general neuroprotective
compounds or compounds re‐purposed from other indications.
HDAC inhibitors including sodium butyrate, SAHA, phenyl
butyrate, trichostatin A (TSA), LBH589 and M344, are the most
commonly studied class of SMN inducers and have all been
reported to increase SMN transcription (Andreassi et al, 2004;
Avila et al, 2007; Brichta et al, 2003; Chang et al, 2001; Garbes
et al, 2009; Hahnen et al, 2006; Riessland et al, 2006; Sumner
et al, 2003). Sodium butyrate and SAHA have also been shown
to increase exon 7 inclusion in SMN2 transcripts. The HDAC
inhibitor VPA has also been characterized as a splicing enhancer
for SMN2 (Brichta et al, 2003).
SMN2 based reporters have been used to identify novel
compounds for the treatment of SMA. Our original splicing
cassette was used in low‐throughput mode to identify the
phosphatase inhibitor sodium orthovanadate (Zhang et al,
2001), aclarubicin (Andreassi et al, 2001) and indoprofen
(Lunn et al, 2004). These compounds have been shown to
increase full‐length SMN protein expression from the SMN2
gene. Sodium orthovanadate, a phosphatase inhibitor, might
affect SR (serine/arginine rich) protein phosphorylation state
and thereby modulate SMN splicing (Zhang et al, 2001).
Interestingly, both aclarubicin and sodium orthovanadate
activities are enhanced in the presence of the transcription
factor Stat5 (signal transducers and activators of transcription 5),
while Stat5 knockout abrogates their effect (Ting et al, 2007).
The hormone prolactin can activate Stat5, which in turn
increases SMN expression (Farooq et al, 2011). In the same
study, prolactin treatment in the SMND7 mice improved gross
motor function and increased survival. This suggests that SMN
expression may be regulated by a signal transduction pathway in
response to cytokines or growth factors. Indoprofen, a non‐
steroidal anti‐inﬂammatory drug, was also identiﬁed using our
ﬁrst generation reporter assay. The mechanism of action for
indoprofen has not been determined but recent evidence
suggests that it has anti‐terminator activity. Aminoglycosides
also have anti‐terminator activity and have been shown to
stabilize the SMND7 protein and presumably increase its
functionality (Heier & DiDonato, 2009; Mattis et al, 2008). An
independent SMN2 promoter screen was used to identify the
2,4 diaminoquinazoline series of compounds (Jarecki et al,
2005). The quinazoline compounds may act by binding to and
inhibiting the scavenger decapping enzyme, DcpS (Singh
et al, 2008). Other modes of action being explored include
proteasome inhibition, SMN stabilization, inhibition or activa-
tion of signal transduction, and targeted regulation of exon 7
inclusion and are currently at different stages of development.
We previously reported a new screen that combined the
beneﬁts of the splicing and transcriptional assays for SMN2
expression (Cherry et al, 2012). In that report, we described
three novel compounds that increased SMN expression in
the reporter cells and were conﬁrmed in 3813 SMA derived
ﬁbroblasts. Early medicinal chemistry efforts revealed that these
compounds lacked the characteristics desired for further
development. Here we characterize two new scaffolds, LDN‐
75654 and LDN‐76070, which induce expression of full‐length
SMN from SMN2. Both compounds increase SMN‐luciferase
expression in the reporter assay and levels of endogenous
SMN protein in 3813 SMA derived primary ﬁbroblasts with
low micromolar EC50s. Neither of the compounds displayed
inhibition of HDAC 3, 6 or 8 activity in vitro. These compounds
also displayed selectivity for SMN2‐luciferase expression
when tested in two additional cell lines for speciﬁcity, SMN1‐
luciferase and the SV40min‐luciferase. These compounds have
been tested in other high throughput screens without being
identiﬁed as hits, suggesting the utility of the multi‐faceted
screening platform.
RT‐PCR analysis conﬁrmed that LDN‐76070 and LDN‐109657
increased the amount of total SMN‐luciferase fusion transcripts,
with a concomitant increase in the amount of full‐length
transcripts (Fig 2B). LDN‐76070 does not share structural
similarity with other compounds shown to increase SMN
expression. The pathway and targets involved in its activity
are still unknown. LDN‐75654 also increased the amount of
detectable SMN‐luciferase fusion protein, but it promoted little
change at the mRNA level. This suggests that LDN‐75654
functions post‐transcriptionally, perhaps by increasing transla-
tion efﬁciency or decreasing SMN protein turnover. Post‐
transcriptional regulation of SMN expression is not without
precedent. The aminoglycosides are anti‐terminators that act
post‐transcriptionally by allowing read through of the stop
codon in exon 8 of the SMND7 transcript (Mattis et al, 2006,
2009; Wolstencroft et al, 2005). The additional amino acids
produced by this read‐through stabilize the SMND7 protein
product. Due to the design of our screen, activity of anti‐
terminators like the aminoglycosides would not be detected.
LDN‐75654 is not structurally similar to aminoglycosides or
other compounds reported to regulate SMN expression.
However, the oxazole carboxamide backbone of LDN‐75654 is
similar to that of leﬂunomide, a pyrimidine synthesis inhibitor
used to treat rheumatoid arthritis (Bartlett et al, 1991; Ruck-
emann et al, 1998). Leﬂunomide was also active in our reporter
screen and was identiﬁed independently using our SMN2‐
luciferase reporter cells (PubChem CID ¼ 3899). We are
currently examining the nature of this similarity.
Investigation of the combinatorial effects of these scaffolds
could provide further insight into their general mechanism of
action and might enhance their therapeutic efﬁcacy. Combining
LDN‐75654 with the transcriptional activators LND‐76070, LDN‐
109657, or SAHA produced a greater than additive stimulation
of the SMN2‐luciferase reporter. This effect was most apparent
when LDN‐75654 was combined with SAHA, which has
been shown to increase both SMN transcription and exon 7
inclusion. We propose that the complementation seen with
these compounds is a conﬁrmation that the compounds are
working through separate and distinct mechanisms to induce
SMN2 expression. The effect of LDN‐76070 was partially masked
by the addition of SAHA. SAHA appears to overwhelm the
transcriptional machinery and blunt the efﬁcacy of LDN‐76070,
suggesting that these compounds stimulate SMN2‐luciferase
expression through similar or overlapping pathways. The
observation that these two compounds still produce a greater
than additive effect in the constant ratio experiments may be due
to the secondary effect that SAHA has on the splicing efﬁciency
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and inclusion of exon 7. The dramatic increase in SMN2‐
luciferase activation observed with the combination of SAHA
with LDN‐75654 suggests that LDN‐75654 augments SMN
expression in addition to the splicing and transcriptional
increases produced by SAHA, possibly through effects on
protein stability or translation.
Systematic delivery of LDN‐76070 promoted greater than
threefold increases in SMN protein levels in the brain and spinal
cord, suggesting the ability to penetrate the blood brain barrier.
It dramatically increased lifespan and gross motor function
in these animals as evidenced by the improvements in TTR
tests. LDN‐76070 displayed excellent stability in mouse liver
microsomes, half‐life of 40 min, but has low aqueous solubility.
While LDN‐75654 promoted increases in SMN expression in
both the reporter assay and SMA derived ﬁbroblasts, treatments
with this compound in pilot experiments with the SMND7
mice resulted in weak and inconsistent increases in SMN
protein levels. LDN‐75654 had a relatively short half‐life of
15 min in in vitro mouse liver microsome assays. We assume
that this lack of metabolic stability accounts for its poor
activity in the animals.
There has been an unprecedented increase in the therapeutic
pipeline for SMA (Cherry & Androphy, 2012; Lorson & Lorson,
2012). Unlike early studies focused on neuroprotective agents
including carnitine, riluzole and more recently olesoxmine and
ceftriaxone, the compounds describe in this manuscript are
designed to target SMN2 expression. The largest class of
compounds that is currently being studied for their ability to
increase SMN expression is the HDAC inhibitors. These have
shown modest extension of lifespan in SMA model mice (Chang
et al, 2001; Riessland et al, 2010), however, VPA and phenyl-
butyrate failed to exhibit signiﬁcant clinical efﬁcacy in human
SMA protocols. Other drug‐like small molecules that have
increased lifespan of SMA mice include an orally bioavailable
quinazoline analog, the aminoglycoside TC007, and prolactin
(Butchbach et al, 2010; Farooq et al, 2011; Mattis et al, 2009).
LDN‐76070 induces SMN2 transcription, while LDN‐75654
acts post‐transcriptionally. Neither inhibited HDAC activity
in vitro. LDN‐76070 treated animals lived an average 11 days
longer than DMSO treated littermates, representing an increase
of lifespan of more than 180%. Despite the apparent DMSO
toxicity, LDN‐76070 treatment still increased the lifespan
of these animals by 48% over that of untreated animals. The
chemical scaffolds described here, derived from a high‐
throughput screen of a chemical diversity library to increase
SMN protein, show promise as these compounds exhibited the
predicted activities in mice. Further work is necessary to
improve their pharmacological properties and determine their
precise mode of action.
MATERIALS AND METHODS
Cell culture
Cells were incubated at 37°C with 5% CO2. HEK‐293 cells were grown
in D‐MEM (Gibco 11995) with 10% foetal bovine serum (FBS Atlas) and
1 pen‐strep (Gibco 15140). Reporter cell lines containing SMN1,
SMN2 or control luciferase reporter were selected andmaintained in D‐
MEM with 10% FBS and 1 pen‐strep with 200 mg/ml hygromycin B
(Invitrogen 10687‐010). Primary human ﬁbroblasts were grown in
D‐MEM with 10% FBS and 1 pen‐strep.
Luciferase assay
SMN2-luciferase, SMN1-luciferase, and SV40min-luciferase reporter
cells (Cherry et al, 2012) were plated in D‐MEM in the absence of
hygromycin B and allowed to adhere 24 h prior to addition of
compound at 37°C with 5% CO2. 25,000 cells were added per well to
96 well white tissue culture treated plates. The ﬁnal DMSO
concentration in each well was 0.1%. Plates were incubated for
25 h. Fireﬂy and renilla luciferase expression were measured using
Dual Glo luciferase substrate (Promega E2920) on the Envision (Perkin–
Elmer). Raw data were collected as counts per second (CPS) with an
integration time of 0.1 s. For normalization all raw data points were
transformed from CPS to percent activation over basal expression in
relation to the DMSO treated control wells.
For the constant ratio combination studies, compounds are then
assayed singly or in pairs at concentrations that equal 8 EC50, 4
EC50, 2 EC50, EC50, 0.5 EC50, 0.25 EC50 and 0.125 EC50. For example,
when LDN‐75654 and SAHA were combined, LDN‐75654 was assayed
alone at 50, 25, 12.5, 6.25, 3.1, 1.6 and 0.78 mM; SAHA was tested
alone at 10, 5, 2.5, 1.25, 0.62, 0.31 and 0.16 mM; and they
were combined in a ratio of 5:1 with paired concentrations of 50:10,
25:5, 12.5:2.5, 6.25:1.25, 3.1:0.62, 1.60:0.31, and 0.78:0.16 mM.
SMN protein detection
For analysis of SMN‐luciferase fusion, cells were treated with
compound or DMSO for 25 h. Cells were lysed with 100 mM
Tris pH 8.0, 100 mM NaCl, 0.1% NP‐40, 8.0 M Urea, and protease
inhibitor. Each sample was separated on a 10% SDS–PAGE gel,
transferred to Immobilon‐P membrane (Millipore IVPH00010) and
blotted for the SMN‐luciferase fusion with anti‐luciferase antibody
(Promega, G7541) as well as actin (Sigma A2066) or a‐tubulin (DM1a;
Sigma T6199).
For detection of SMN protein in patient ﬁbroblasts, 8,000 cells per
cm2 were plated 24 h prior to drug addition. Fresh media and
compound were added every 24 h. After 72 h, cells were harvested,
washed with cold PBS, and lysed as above. We have determined that
10 mg total protein per lane is within the linear range for immunoblot
detection of SMN and a‐tubulin. Western blots were probed for SMN
with the 4f11 mouse monoclonal antibody and a‐tubulin.
Quantiﬁcation of protein was performed with Fujiﬁlm LAS‐4000
Multifunctional Imaging System. The signal intensity was measured for
each band on an immunoblot, normalized to the loading control, and
the fold increase was determined in relation to the appropriate DMSO
treated control.
Microscopy and gem analysis
Gem counts were performed as previously described (Mattis
et al, 2006). Brieﬂy, cells were grown on poly(D) lysine treated cover
slips, ﬁxed in methanol, and stained with DAPI and reacted with a
SMN monoclonal antibody and an Alexa‐488 conjugated secondary
antibody. Approximately 100 cells from were visually scored for
the number of gems and the number of gems per 100 nuclei
calculated.
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PCR and RT‐PCR
For analysis of SMN‐luciferase fusion expression, compounds were
tested at three concentrations that display maximal activity in the
luciferase assay. Cells were treated as described above for the luciferase
assay. Cells were harvested by trypsinization, neutralized with trypsin
inhibitor, and washed. 10% of each cell pellet was resuspended and
plated into three wells of a 96‐well dish and used to analyse luciferase
activity by DualGlo luciferase assay (Promega E2920). RNAwas isolated
from the remaining cells using Trizol Reagent (Invitrogen 15596‐026).
cDNA was generated using the Improm‐II Reverse Transcription System
(Promega A3801).
The forward primer pair recognizes the exon 5–6 junction, which
includes a restriction site that was engineered into the reporter andwill
exclude ampliﬁcation of endogenous SMN mRNA. The reverse primers
recognize either exon 7 or luciferase for detection of full‐length or total
SMN‐luciferase transcripts respectively. For a reference control, we
ampliﬁed cDNA from the housekeeping gene glyceraldehyde‐3‐
phosphate dehydrogenase (GAPDH).
Primer sequences were as follows; SMN exon5‐FWR (50‐
catttccttctggaccactcgag‐30), Luciferase‐REV (50‐atagcttctgccaacc-
gaacgg‐30), Exon7‐REV (50‐taaggaatgtgagcaccttccttc‐30), GAPDH‐REV
(G3A) (50‐tccaccaccctgttgctgta‐30), and GAPDH‐FWR (G3S) (50‐acca-
cagtccatgccatcac‐30).
qPCR was performed as described in the protocol for iQ SybrGreen
Supermix (BioRad 170‐8882) using an Eppendorf Mastercycler ep
realplex 4 real‐time PCR machine. Reactions were incubated for a
10 min 94°C hot start followed by 45 cycles of the following: 94°C for
45 s, 60°C for 15 s, 72°C for 45 s. Melting curves for each reaction
were obtained. Each sample was assayed in triplicate and every plate
contained a ﬁve‐point cDNA dilution course to calculate ampliﬁcation
efﬁciency for each primer pair. The Pfafﬂ method was used to
determine the change in transcript levels relative to the DMSO and
normalized to GAPDH (Pfafﬂ, 2001).
Animal procedures and experiments
All animal experiments were carried out in accordance with protocols
approved by the Animal Care and Use Committee of the University of
Missouri. Original breeder pairs of Smnþ/; SMN2þ/þ; SMND7þ/þ mice
were purchased from The Jackson Laboratory (JAX® Mice and Services,
610 Main Street Bar Harbor, ME 04609 USA). Offspring were
genotyped on the day of birth as previously described (Coady &
Lorson, 2010) using primer sets for the Smn gene: mSmn‐WT FWD (50‐
tctgtgttcgtgcgtggtgacttt‐30) and mSmn‐WT REV (50‐cccaccacctaa-
gaaagcctcaat‐30) and for the Smn knockout: SMN1‐KO FWD (50‐
ccaacttaatcgccttgcagcaca‐30) and SMN1‐KO REV (50‐aagcgagtggcaa-
catggaaatcg‐30) utilizing multiplex PCR on tail biopsy material.
Both treated and untreated control SMA mice were raised with
two unaffected heterozygous siblings to control for litter size. ICV
injections were performed as previously described (Coady et al,
2008; Passini & Wolfe, 2001). Brieﬂy, mice were immobilized via cryo‐
anesthesia and injected using ml calibrated sterilized glass micro-
pipettes. The injection site was approximately 0.25 mm lateral to the
sagittal suture and 0.50–0.75 mm rostral to the neonatal coronary
suture. The needles were inserted perpendicular to the skull surface
using a ﬁbre‐optic light (Boyce Scientiﬁc Inc.) to aid in illuminating
pertinent anatomical structures. Needles were removed after 5 s of
discontinuation of plunger movement to prevent backﬂow. Mice
recovered for 5–10 min in a warmed container until movement was
restored.
Time‐to‐right (TTR) was performed on ﬂat surface and the test was
terminated at 30 s. If an animal had not turned by this time, it was
recorded as ‘Failure.’ TTR success rate and speed tests were initiated on
The paper explained
PROBLEM:
SMA is the most common cause of infant mortality worldwide.
SMA has a carrier rate of 1 in 40 and the disease incidence is 1 in
11,000 live births. It is a neurodegenerative disorder that can
progress rapidly. In the most severe cases, symptoms present
within the first 6 months of life and death usually occurs within
the first 2 years. There is no approved treatment for SMA. New
oligo and gene replacement based therapies are showing
promise. Existing small molecule therapies have not been
effective in human clinical trials.
RESULT:
The presence of the SMN2 gene in nearly all SMA patients
provides an attractive therapeutic target for the treatment of
SMA.We present two new series of small molecules that increase
the levels of SMN protein derived from the SMN2 gene. The
compounds in these series utilize separate and potentially
unique mechanisms of action. They are active in SMN reporter
cell lines, primary SMN patient fibroblasts, and, in the case of
compound LDN-76070, display in vivo efficacy with the SMAD7
mice.
IMPACT:
There is a clear need for new therapeutic smallmolecules in the SMA
drug pipeline. The data presented here confirms that these new
compounds can increase SMNprotein levels in both cells andanSMA
model animal. The exciting in vivo proof-of-principle data with LDN-
76070 in the SMND7mice confirms that it can cross the blood brain
barrier in neonates and induce protein levels in the spinal cord to
nearly 90% percent of that found in asymptomatic littermates that
are heterozygous for Smn1. LDN-76070 also promotes an increase in
survival and improvement in gross motor function in these animals.
Medicinal chemistry efforts are underway on compounds in both
series to improve their pharmacokinetic characteristics; including
solubility, metabolic stability, and potency. These compound
represent two new and unique series of compounds that might be
developed as clinical leads for the treatment of SMA.
Research Articlewww.embomolmed.org
Jonathan J. Cherry et al.
EMBO Mol Med (2013) 5, 1103–1118  2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1115
PND7 since unaffected animals start to turn over at this time; trials
concluded on PND20.
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